ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).
Identifieur interne : 000931 ( Main/Exploration ); précédent : 000930; suivant : 000932ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).
Auteurs : J W Baddley [États-Unis] ; F. Cantini [Italie] ; D. Goletti [Italie] ; J J G Mez-Reino [Espagne] ; E. Mylonakis [États-Unis] ; R. San-Juan [Espagne] ; M. Fernández-Ruiz [Espagne] ; J. Torre-Cisneros [Espagne]Source :
- Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases [ 1469-0691 ] ; 2018.
Descripteurs français
- KwdFr :
- Adalimumab (effets indésirables), Adalimumab (usage thérapeutique), Anti-inflammatoires (administration et posologie), Anti-inflammatoires (effets indésirables), Anticorps monoclonaux (administration et posologie), Anticorps monoclonaux (effets indésirables), Anticorps monoclonaux (usage thérapeutique), Biothérapie (effets indésirables), Biothérapie (méthodes), Contrôle des maladies transmissibles (MeSH), Essais cliniques comme sujet (MeSH), Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs), Facteur de nécrose tumorale alpha (immunologie), Facteurs immunologiques (usage thérapeutique), Humains (MeSH), Hépatite B chronique (prévention et contrôle), Hépatite B chronique (traitement médicamenteux), Infliximab (effets indésirables), Infliximab (usage thérapeutique), Maladies transmissibles (immunologie), Maladies transmissibles (thérapie), Sujet immunodéprimé (MeSH), Thérapie moléculaire ciblée (effets indésirables), Thérapie moléculaire ciblée (méthodes), Tuberculose latente (prévention et contrôle), Vaccins antiviraux (administration et posologie), Étanercept (administration et posologie), Étanercept (effets indésirables).
- MESH :
- administration et posologie : Anti-inflammatoires, Anticorps monoclonaux, Vaccins antiviraux, Étanercept.
- antagonistes et inhibiteurs : Facteur de nécrose tumorale alpha.
- effets indésirables : Adalimumab, Anti-inflammatoires, Anticorps monoclonaux, Biothérapie, Infliximab, Thérapie moléculaire ciblée, Étanercept.
- immunologie : Facteur de nécrose tumorale alpha, Maladies transmissibles.
- méthodes : Biothérapie, Thérapie moléculaire ciblée.
- prévention et contrôle : Hépatite B chronique, Tuberculose latente.
- thérapie : Maladies transmissibles.
- traitement médicamenteux : Hépatite B chronique.
- usage thérapeutique : Adalimumab, Anticorps monoclonaux, Facteurs immunologiques, Infliximab.
- Contrôle des maladies transmissibles, Essais cliniques comme sujet, Humains, Sujet immunodéprimé.
English descriptors
- KwdEn :
- Adalimumab (adverse effects), Adalimumab (therapeutic use), Anti-Inflammatory Agents (administration & dosage), Anti-Inflammatory Agents (adverse effects), Antibodies, Monoclonal (administration & dosage), Antibodies, Monoclonal (adverse effects), Antibodies, Monoclonal (therapeutic use), Biological Therapy (adverse effects), Biological Therapy (methods), Clinical Trials as Topic (MeSH), Communicable Disease Control (MeSH), Communicable Diseases (immunology), Communicable Diseases (therapy), Etanercept (administration & dosage), Etanercept (adverse effects), Hepatitis B, Chronic (drug therapy), Hepatitis B, Chronic (prevention & control), Humans (MeSH), Immunocompromised Host (MeSH), Immunologic Factors (therapeutic use), Infliximab (adverse effects), Infliximab (therapeutic use), Latent Tuberculosis (prevention & control), Molecular Targeted Therapy (adverse effects), Molecular Targeted Therapy (methods), Tumor Necrosis Factor-alpha (antagonists & inhibitors), Tumor Necrosis Factor-alpha (immunology), Viral Vaccines (administration & dosage).
- MESH :
- chemical , administration & dosage : Anti-Inflammatory Agents, Antibodies, Monoclonal, Etanercept, Viral Vaccines.
- chemical , adverse effects : Adalimumab, Anti-Inflammatory Agents, Antibodies, Monoclonal, Etanercept, Infliximab.
- chemical , antagonists & inhibitors : Tumor Necrosis Factor-alpha.
- chemical , immunology : Tumor Necrosis Factor-alpha.
- chemical , therapeutic use : Adalimumab, Antibodies, Monoclonal, Immunologic Factors, Infliximab.
- adverse effects : Biological Therapy, Molecular Targeted Therapy.
- drug therapy : Hepatitis B, Chronic.
- immunology : Communicable Diseases.
- methods : Biological Therapy, Molecular Targeted Therapy.
- prevention & control : Hepatitis B, Chronic, Latent Tuberculosis.
- therapy : Communicable Diseases.
- Clinical Trials as Topic, Communicable Disease Control, Humans, Immunocompromised Host.
Abstract
BACKGROUND
The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies.
AIMS
To review, from an Infectious Diseases perspective, the safety profile of agents targeting tumour necrosis factor-α (TNF-α) and to suggest preventive recommendations.
SOURCES
Computer-based MEDLINE searches with MeSH terms pertaining to each agent or therapeutic family.
CONTENT
Preclinical and clinical evidence indicate that anti-TNF-α therapy (infliximab, adalimumab, golimumab, certolizumab pegol and etanercept) is associated with a two-to four-fold increase in the risk of active tuberculosis and other granulomatous conditions (mostly resulting from the reactivation of a latent infection). In addition, it may lead to the occurrence of other serious infections (bacterial, fungal, opportunistic and certain viral infections). These associated risks seem to be lower for etanercept than other agents. Screening for latent tuberculosis infection should be performed before starting anti-TNF-α therapy, followed by anti-tuberculosis therapy if appropriate. Screening for chronic hepatitis B virus (HBV) infection is also recommended, and antiviral prophylaxis may be warranted for hepatitis B surface antigen-positive individuals. No benefit is expected from the use of antibacterial, anti-Pneumocystis or antifungal prophylaxis. Pneumococcal and age-appropriate antiviral vaccinations (i.e. influenza) should be administered. Live-virus vaccines (i.e. varicella-zoster virus or measles-mumps-rubella) may be contraindicated in people receiving anti-TNF-α therapy, although additional data are needed before definitive recommendations can be made.
IMPLICATIONS
Prevention measures should be implemented to reduce the risk of latent tuberculosis or HBV reactivation among individuals receiving anti-TNF-α therapy.
DOI: 10.1016/j.cmi.2017.12.025
PubMed: 29459143
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).</title><author><name sortKey="Baddley, J W" sort="Baddley, J W" uniqKey="Baddley J" first="J W" last="Baddley">J W Baddley</name><affiliation wicri:level="2"><nlm:affiliation>Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: jbaddley@uabmc.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author><author><name sortKey="Cantini, F" sort="Cantini, F" uniqKey="Cantini F" first="F" last="Cantini">F. Cantini</name><affiliation wicri:level="1"><nlm:affiliation>Division of Rheumatology, Hospital of Prato, Prato, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Rheumatology, Hospital of Prato, Prato</wicri:regionArea><wicri:noRegion>Prato</wicri:noRegion></affiliation></author><author><name sortKey="Goletti, D" sort="Goletti, D" uniqKey="Goletti D" first="D" last="Goletti">D. Goletti</name><affiliation wicri:level="3"><nlm:affiliation>Department of Epidemiology and Preclinical Research, Translational Research Unit, National Institute for Infectious Diseases 'Lazzaro Spallanzani', Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Epidemiology and Preclinical Research, Translational Research Unit, National Institute for Infectious Diseases 'Lazzaro Spallanzani', Rome</wicri:regionArea><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author><author><name sortKey="G Mez Reino, J J" sort="G Mez Reino, J J" uniqKey="G Mez Reino J" first="J J" last="G Mez-Reino">J J G Mez-Reino</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Rheumatology, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela</wicri:regionArea><wicri:noRegion>Santiago de Compostela</wicri:noRegion></affiliation></author><author><name sortKey="Mylonakis, E" sort="Mylonakis, E" uniqKey="Mylonakis E" first="E" last="Mylonakis">E. Mylonakis</name><affiliation wicri:level="2"><nlm:affiliation>Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence, RI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence, RI</wicri:regionArea><placeName><region type="state">Rhode Island</region></placeName></affiliation></author><author><name sortKey="San Juan, R" sort="San Juan, R" uniqKey="San Juan R" first="R" last="San-Juan">R. San-Juan</name><affiliation wicri:level="3"><nlm:affiliation>Unit of Infectious Diseases, Hospital Universitario '12 de Octubre', Instituto de Investigación Hospital '12 de Octubre' (i+12), School of Medicine, Universidad Complutense, Madrid, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), Instituto de Salud Carlos III, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Unit of Infectious Diseases, Hospital Universitario '12 de Octubre', Instituto de Investigación Hospital '12 de Octubre' (i+12), School of Medicine, Universidad Complutense, Madrid, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), Instituto de Salud Carlos III, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Fernandez Ruiz, M" sort="Fernandez Ruiz, M" uniqKey="Fernandez Ruiz M" first="M" last="Fernández-Ruiz">M. Fernández-Ruiz</name><affiliation wicri:level="3"><nlm:affiliation>Unit of Infectious Diseases, Hospital Universitario '12 de Octubre', Instituto de Investigación Hospital '12 de Octubre' (i+12), School of Medicine, Universidad Complutense, Madrid, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), Instituto de Salud Carlos III, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Unit of Infectious Diseases, Hospital Universitario '12 de Octubre', Instituto de Investigación Hospital '12 de Octubre' (i+12), School of Medicine, Universidad Complutense, Madrid, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), Instituto de Salud Carlos III, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Torre Cisneros, J" sort="Torre Cisneros, J" uniqKey="Torre Cisneros J" first="J" last="Torre-Cisneros">J. Torre-Cisneros</name><affiliation wicri:level="3"><nlm:affiliation>Clinical Unit of Infectious Diseases, University Hospital 'Reina Sofía', Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), School of Medicine, University of Córdoba, Córdoba, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), Instituto de Salud Carlos III, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Clinical Unit of Infectious Diseases, University Hospital 'Reina Sofía', Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), School of Medicine, University of Córdoba, Córdoba, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), Instituto de Salud Carlos III, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29459143</idno><idno type="pmid">29459143</idno><idno type="doi">10.1016/j.cmi.2017.12.025</idno><idno type="wicri:Area/Main/Corpus">000941</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000941</idno><idno type="wicri:Area/Main/Curation">000941</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000941</idno><idno type="wicri:Area/Main/Exploration">000941</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).</title><author><name sortKey="Baddley, J W" sort="Baddley, J W" uniqKey="Baddley J" first="J W" last="Baddley">J W Baddley</name><affiliation wicri:level="2"><nlm:affiliation>Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: jbaddley@uabmc.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author><author><name sortKey="Cantini, F" sort="Cantini, F" uniqKey="Cantini F" first="F" last="Cantini">F. Cantini</name><affiliation wicri:level="1"><nlm:affiliation>Division of Rheumatology, Hospital of Prato, Prato, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Rheumatology, Hospital of Prato, Prato</wicri:regionArea><wicri:noRegion>Prato</wicri:noRegion></affiliation></author><author><name sortKey="Goletti, D" sort="Goletti, D" uniqKey="Goletti D" first="D" last="Goletti">D. Goletti</name><affiliation wicri:level="3"><nlm:affiliation>Department of Epidemiology and Preclinical Research, Translational Research Unit, National Institute for Infectious Diseases 'Lazzaro Spallanzani', Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Epidemiology and Preclinical Research, Translational Research Unit, National Institute for Infectious Diseases 'Lazzaro Spallanzani', Rome</wicri:regionArea><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author><author><name sortKey="G Mez Reino, J J" sort="G Mez Reino, J J" uniqKey="G Mez Reino J" first="J J" last="G Mez-Reino">J J G Mez-Reino</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Rheumatology, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela</wicri:regionArea><wicri:noRegion>Santiago de Compostela</wicri:noRegion></affiliation></author><author><name sortKey="Mylonakis, E" sort="Mylonakis, E" uniqKey="Mylonakis E" first="E" last="Mylonakis">E. Mylonakis</name><affiliation wicri:level="2"><nlm:affiliation>Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence, RI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence, RI</wicri:regionArea><placeName><region type="state">Rhode Island</region></placeName></affiliation></author><author><name sortKey="San Juan, R" sort="San Juan, R" uniqKey="San Juan R" first="R" last="San-Juan">R. San-Juan</name><affiliation wicri:level="3"><nlm:affiliation>Unit of Infectious Diseases, Hospital Universitario '12 de Octubre', Instituto de Investigación Hospital '12 de Octubre' (i+12), School of Medicine, Universidad Complutense, Madrid, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), Instituto de Salud Carlos III, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Unit of Infectious Diseases, Hospital Universitario '12 de Octubre', Instituto de Investigación Hospital '12 de Octubre' (i+12), School of Medicine, Universidad Complutense, Madrid, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), Instituto de Salud Carlos III, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Fernandez Ruiz, M" sort="Fernandez Ruiz, M" uniqKey="Fernandez Ruiz M" first="M" last="Fernández-Ruiz">M. Fernández-Ruiz</name><affiliation wicri:level="3"><nlm:affiliation>Unit of Infectious Diseases, Hospital Universitario '12 de Octubre', Instituto de Investigación Hospital '12 de Octubre' (i+12), School of Medicine, Universidad Complutense, Madrid, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), Instituto de Salud Carlos III, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Unit of Infectious Diseases, Hospital Universitario '12 de Octubre', Instituto de Investigación Hospital '12 de Octubre' (i+12), School of Medicine, Universidad Complutense, Madrid, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), Instituto de Salud Carlos III, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Torre Cisneros, J" sort="Torre Cisneros, J" uniqKey="Torre Cisneros J" first="J" last="Torre-Cisneros">J. Torre-Cisneros</name><affiliation wicri:level="3"><nlm:affiliation>Clinical Unit of Infectious Diseases, University Hospital 'Reina Sofía', Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), School of Medicine, University of Córdoba, Córdoba, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), Instituto de Salud Carlos III, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Clinical Unit of Infectious Diseases, University Hospital 'Reina Sofía', Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), School of Medicine, University of Córdoba, Córdoba, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), Instituto de Salud Carlos III, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author></analytic><series><title level="j">Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</title><idno type="eISSN">1469-0691</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adalimumab (adverse effects)</term><term>Adalimumab (therapeutic use)</term><term>Anti-Inflammatory Agents (administration & dosage)</term><term>Anti-Inflammatory Agents (adverse effects)</term><term>Antibodies, Monoclonal (administration & dosage)</term><term>Antibodies, Monoclonal (adverse effects)</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Biological Therapy (adverse effects)</term><term>Biological Therapy (methods)</term><term>Clinical Trials as Topic (MeSH)</term><term>Communicable Disease Control (MeSH)</term><term>Communicable Diseases (immunology)</term><term>Communicable Diseases (therapy)</term><term>Etanercept (administration & dosage)</term><term>Etanercept (adverse effects)</term><term>Hepatitis B, Chronic (drug therapy)</term><term>Hepatitis B, Chronic (prevention & control)</term><term>Humans (MeSH)</term><term>Immunocompromised Host (MeSH)</term><term>Immunologic Factors (therapeutic use)</term><term>Infliximab (adverse effects)</term><term>Infliximab (therapeutic use)</term><term>Latent Tuberculosis (prevention & control)</term><term>Molecular Targeted Therapy (adverse effects)</term><term>Molecular Targeted Therapy (methods)</term><term>Tumor Necrosis Factor-alpha (antagonists & inhibitors)</term><term>Tumor Necrosis Factor-alpha (immunology)</term><term>Viral Vaccines (administration & dosage)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adalimumab (effets indésirables)</term><term>Adalimumab (usage thérapeutique)</term><term>Anti-inflammatoires (administration et posologie)</term><term>Anti-inflammatoires (effets indésirables)</term><term>Anticorps monoclonaux (administration et posologie)</term><term>Anticorps monoclonaux (effets indésirables)</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Biothérapie (effets indésirables)</term><term>Biothérapie (méthodes)</term><term>Contrôle des maladies transmissibles (MeSH)</term><term>Essais cliniques comme sujet (MeSH)</term><term>Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs)</term><term>Facteur de nécrose tumorale alpha (immunologie)</term><term>Facteurs immunologiques (usage thérapeutique)</term><term>Humains (MeSH)</term><term>Hépatite B chronique (prévention et contrôle)</term><term>Hépatite B chronique (traitement médicamenteux)</term><term>Infliximab (effets indésirables)</term><term>Infliximab (usage thérapeutique)</term><term>Maladies transmissibles (immunologie)</term><term>Maladies transmissibles (thérapie)</term><term>Sujet immunodéprimé (MeSH)</term><term>Thérapie moléculaire ciblée (effets indésirables)</term><term>Thérapie moléculaire ciblée (méthodes)</term><term>Tuberculose latente (prévention et contrôle)</term><term>Vaccins antiviraux (administration et posologie)</term><term>Étanercept (administration et posologie)</term><term>Étanercept (effets indésirables)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Inflammatory Agents</term><term>Antibodies, Monoclonal</term><term>Etanercept</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Adalimumab</term><term>Anti-Inflammatory Agents</term><term>Antibodies, Monoclonal</term><term>Etanercept</term><term>Infliximab</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adalimumab</term><term>Antibodies, Monoclonal</term><term>Immunologic Factors</term><term>Infliximab</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anti-inflammatoires</term><term>Anticorps monoclonaux</term><term>Vaccins antiviraux</term><term>Étanercept</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Biological Therapy</term><term>Molecular Targeted Therapy</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteur de nécrose tumorale alpha</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hepatitis B, Chronic</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Adalimumab</term><term>Anti-inflammatoires</term><term>Anticorps monoclonaux</term><term>Biothérapie</term><term>Infliximab</term><term>Thérapie moléculaire ciblée</term><term>Étanercept</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Facteur de nécrose tumorale alpha</term><term>Maladies transmissibles</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Communicable Diseases</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Biological Therapy</term><term>Molecular Targeted Therapy</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Biothérapie</term><term>Thérapie moléculaire ciblée</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Hepatitis B, Chronic</term><term>Latent Tuberculosis</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Hépatite B chronique</term><term>Tuberculose latente</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Communicable Diseases</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Maladies transmissibles</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hépatite B chronique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Adalimumab</term><term>Anticorps monoclonaux</term><term>Facteurs immunologiques</term><term>Infliximab</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term><term>Communicable Disease Control</term><term>Humans</term><term>Immunocompromised Host</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Contrôle des maladies transmissibles</term><term>Essais cliniques comme sujet</term><term>Humains</term><term>Sujet immunodéprimé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies.</p></div><div type="abstract" xml:lang="en"><p><b>AIMS</b></p><p>To review, from an Infectious Diseases perspective, the safety profile of agents targeting tumour necrosis factor-α (TNF-α) and to suggest preventive recommendations.</p></div><div type="abstract" xml:lang="en"><p><b>SOURCES</b></p><p>Computer-based MEDLINE searches with MeSH terms pertaining to each agent or therapeutic family.</p></div><div type="abstract" xml:lang="en"><p><b>CONTENT</b></p><p>Preclinical and clinical evidence indicate that anti-TNF-α therapy (infliximab, adalimumab, golimumab, certolizumab pegol and etanercept) is associated with a two-to four-fold increase in the risk of active tuberculosis and other granulomatous conditions (mostly resulting from the reactivation of a latent infection). In addition, it may lead to the occurrence of other serious infections (bacterial, fungal, opportunistic and certain viral infections). These associated risks seem to be lower for etanercept than other agents. Screening for latent tuberculosis infection should be performed before starting anti-TNF-α therapy, followed by anti-tuberculosis therapy if appropriate. Screening for chronic hepatitis B virus (HBV) infection is also recommended, and antiviral prophylaxis may be warranted for hepatitis B surface antigen-positive individuals. No benefit is expected from the use of antibacterial, anti-Pneumocystis or antifungal prophylaxis. Pneumococcal and age-appropriate antiviral vaccinations (i.e. influenza) should be administered. Live-virus vaccines (i.e. varicella-zoster virus or measles-mumps-rubella) may be contraindicated in people receiving anti-TNF-α therapy, although additional data are needed before definitive recommendations can be made.</p></div><div type="abstract" xml:lang="en"><p><b>IMPLICATIONS</b></p><p>Prevention measures should be implemented to reduce the risk of latent tuberculosis or HBV reactivation among individuals receiving anti-TNF-α therapy.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29459143</PMID><DateCompleted><Year>2018</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-0691</ISSN><JournalIssue CitedMedium="Internet"><Volume>24 Suppl 2</Volume><PubDate><Year>2018</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</Title><ISOAbbreviation>Clin Microbiol Infect</ISOAbbreviation></Journal><ArticleTitle>ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).</ArticleTitle><Pagination><MedlinePgn>S10-S20</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1198-743X(18)30030-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cmi.2017.12.025</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To review, from an Infectious Diseases perspective, the safety profile of agents targeting tumour necrosis factor-α (TNF-α) and to suggest preventive recommendations.</AbstractText><AbstractText Label="SOURCES" NlmCategory="METHODS">Computer-based MEDLINE searches with MeSH terms pertaining to each agent or therapeutic family.</AbstractText><AbstractText Label="CONTENT" NlmCategory="BACKGROUND">Preclinical and clinical evidence indicate that anti-TNF-α therapy (infliximab, adalimumab, golimumab, certolizumab pegol and etanercept) is associated with a two-to four-fold increase in the risk of active tuberculosis and other granulomatous conditions (mostly resulting from the reactivation of a latent infection). In addition, it may lead to the occurrence of other serious infections (bacterial, fungal, opportunistic and certain viral infections). These associated risks seem to be lower for etanercept than other agents. Screening for latent tuberculosis infection should be performed before starting anti-TNF-α therapy, followed by anti-tuberculosis therapy if appropriate. Screening for chronic hepatitis B virus (HBV) infection is also recommended, and antiviral prophylaxis may be warranted for hepatitis B surface antigen-positive individuals. No benefit is expected from the use of antibacterial, anti-Pneumocystis or antifungal prophylaxis. Pneumococcal and age-appropriate antiviral vaccinations (i.e. influenza) should be administered. Live-virus vaccines (i.e. varicella-zoster virus or measles-mumps-rubella) may be contraindicated in people receiving anti-TNF-α therapy, although additional data are needed before definitive recommendations can be made.</AbstractText><AbstractText Label="IMPLICATIONS" NlmCategory="CONCLUSIONS">Prevention measures should be implemented to reduce the risk of latent tuberculosis or HBV reactivation among individuals receiving anti-TNF-α therapy.</AbstractText><CopyrightInformation>Copyright © 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baddley</LastName><ForeName>J W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: jbaddley@uabmc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantini</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Hospital of Prato, Prato, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goletti</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Preclinical Research, Translational Research Unit, National Institute for Infectious Diseases 'Lazzaro Spallanzani', Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gómez-Reino</LastName><ForeName>J J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mylonakis</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>San-Juan</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unit of Infectious Diseases, Hospital Universitario '12 de Octubre', Instituto de Investigación Hospital '12 de Octubre' (i+12), School of Medicine, Universidad Complutense, Madrid, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernández-Ruiz</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unit of Infectious Diseases, Hospital Universitario '12 de Octubre', Instituto de Investigación Hospital '12 de Octubre' (i+12), School of Medicine, Universidad Complutense, Madrid, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torre-Cisneros</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Unit of Infectious Diseases, University Hospital 'Reina Sofía', Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), School of Medicine, University of Córdoba, Córdoba, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016446">Consensus Development Conference</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Microbiol Infect</MedlineTA><NlmUniqueID>9516420</NlmUniqueID><ISSNLinking>1198-743X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C439524">TNF protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>91X1KLU43E</RegistryNumber><NameOfSubstance UI="C529000">golimumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>B72HH48FLU</RegistryNumber><NameOfSubstance UI="D000069285">Infliximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>FYS6T7F842</RegistryNumber><NameOfSubstance UI="D000068879">Adalimumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>OP401G7OJC</RegistryNumber><NameOfSubstance UI="D000068800">Etanercept</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000068879" MajorTopicYN="N">Adalimumab</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001691" MajorTopicYN="N">Biological Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003140" MajorTopicYN="N">Communicable Disease Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003141" MajorTopicYN="N">Communicable Diseases</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068800" MajorTopicYN="N">Etanercept</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019694" MajorTopicYN="N">Hepatitis B, Chronic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016867" MajorTopicYN="N">Immunocompromised Host</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069285" MajorTopicYN="N">Infliximab</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055985" MajorTopicYN="N">Latent Tuberculosis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adalimumab</Keyword><Keyword MajorTopicYN="N">Certolizumab pegol</Keyword><Keyword MajorTopicYN="N">Etanercept</Keyword><Keyword MajorTopicYN="N">Golimumab</Keyword><Keyword MajorTopicYN="N">Infection</Keyword><Keyword MajorTopicYN="N">Infliximab</Keyword><Keyword MajorTopicYN="N">Prevention</Keyword><Keyword MajorTopicYN="N">Tuberculosis</Keyword><Keyword MajorTopicYN="N">Tumour necrosis factor-α</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>12</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29459143</ArticleId><ArticleId IdType="pii">S1198-743X(18)30030-2</ArticleId><ArticleId IdType="doi">10.1016/j.cmi.2017.12.025</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li><li>Italie</li><li>États-Unis</li></country><region><li>Alabama</li><li>Communauté de Madrid</li><li>Latium</li><li>Rhode Island</li></region><settlement><li>Madrid</li><li>Rome</li></settlement></list><tree><country name="États-Unis"><region name="Alabama"><name sortKey="Baddley, J W" sort="Baddley, J W" uniqKey="Baddley J" first="J W" last="Baddley">J W Baddley</name></region><name sortKey="Mylonakis, E" sort="Mylonakis, E" uniqKey="Mylonakis E" first="E" last="Mylonakis">E. Mylonakis</name></country><country name="Italie"><noRegion><name sortKey="Cantini, F" sort="Cantini, F" uniqKey="Cantini F" first="F" last="Cantini">F. Cantini</name></noRegion><name sortKey="Goletti, D" sort="Goletti, D" uniqKey="Goletti D" first="D" last="Goletti">D. Goletti</name></country><country name="Espagne"><noRegion><name sortKey="G Mez Reino, J J" sort="G Mez Reino, J J" uniqKey="G Mez Reino J" first="J J" last="G Mez-Reino">J J G Mez-Reino</name></noRegion><name sortKey="Fernandez Ruiz, M" sort="Fernandez Ruiz, M" uniqKey="Fernandez Ruiz M" first="M" last="Fernández-Ruiz">M. Fernández-Ruiz</name><name sortKey="San Juan, R" sort="San Juan, R" uniqKey="San Juan R" first="R" last="San-Juan">R. San-Juan</name><name sortKey="Torre Cisneros, J" sort="Torre Cisneros, J" uniqKey="Torre Cisneros J" first="J" last="Torre-Cisneros">J. Torre-Cisneros</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/BiopestPeptidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000931 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000931 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= BiopestPeptidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:29459143
|texte= ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:29459143" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a BiopestPeptidV1
| This area was generated with Dilib version V0.6.38. |  |